APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Aprea Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.53−0.05 (-8.88%)
Close on Oct 19, 2026
- Market cap
- $28.47M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
20.5%
3M of 13M shares
Institutional holders
28
8 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $61.04K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| AIGH Capital Management LLC | 651,747 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Jon M. Plexico | 286,395 | 5.10% | 13G (passive) amendment | Dec 31, 2024 |
| Ryan Wilder | 22,654,832 | 9.90% | 13G (passive) | Mar 31, 2026 |
| Squadron Capital Management LLC | 1,271,081 | 9.90% | 13G (passive) | Mar 30, 2026 |
| Soleus GP, LLC | 1,271,080 | 9.99% | 13G (passive) | Apr 1, 2026 |
| Orin Hirschman | 1,186,294 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of APRE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 1,015,541 | 8.07% | $814.77K | – | 0.05% |
| Nantahala Capital Management, LLC | 411,520 | 3.27% | $330.16K | +205,760 | 0.01% |
| Vestal Point Capital, LP | 350,000 | 2.78% | $280.81K | – | 0.01% |
| Sphera Funds Management Ltd. | 270,000 | 2.14% | $216.62K | – | 0.03% |
| Renaissance Technologies LLC | 105,800 | 0.84% | $84.88K | +80,700 | 0.00% |
| Geode Capital Management, LLC | 74,869 | 0.59% | $60.07K | −44,262 | 0.00% |
| Citadel Advisors LLC | 58,600 | 0.47% | $47.02K | New | 0.00% |
| Bnp Paribas Arbitrage, Snc | 45,211 | 0.36% | $36.27K | +5,394 | 0.00% |
| Diadema Partners LP | 44,907 | 0.36% | $36.03K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 38,464 | 0.31% | $30.85K | – | 0.00% |
| Susquehanna International Group, Llp | 34,939 | 0.28% | $28.03K | +21,921 | 0.00% |
| Morgan Stanley | 25,830 | 0.21% | $20.72K | +3,500 | 0.00% |
| Vanguard Capital Management LLC | 22,882 | 0.18% | $18.35K | +3,260 | 0.00% |
| LPL Financial LLC | 16,052 | 0.13% | $12.88K | −5,000 | 0.00% |
| HighTower Advisors, LLC | 13,864 | 0.11% | $11.12K | – | 0.00% |
| Northern Trust Corp | 13,705 | 0.11% | $11.00K | New | 0.00% |
| Persistent Asset Partners Ltd | 11,490 | 0.09% | $9.22K | New | 0.00% |
| XTX Topco Ltd | 10,565 | 0.08% | $8.48K | New | 0.00% |
| BlackRock, Inc. | 7,173 | 0.06% | $5.76K | −1,331 | 0.00% |
| Tower Research Capital LLC (TRC) | 3,590 | 0.03% | $2.88K | −1,537 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 28 | 3M | 20.5% | 8 / 6 | 5 / 2 | 0M | 0M |
| Q1 2026 | 22 | 2M | 17.8% | 7 / 4 | 5 / 6 | 1M | 1M |
| Q4 2025 | 22 | 2M | 13.5% | 5 / 5 | 6 / 6 | 1M | 1M |
| Q3 2025 | 23 | 2M | 12.9% | 2 / 5 | 6 / 2 | 0M | 0M |
| Q2 2025 | 23 | 2M | 14.4% | 1 / 7 | 4 / 4 | 0M | 0M |
| Q1 2025 | 26 | 2M | 15.5% | 1 / 4 | 7 / 1 | 0M | 0M |
| Q4 2024 | 26 | 2M | 16.5% | 5 / 5 | 5 / 0 | 0M | 0M |
| Q3 2024 | 21 | 2M | 17.0% | 1 / 6 | 5 / 6 | 0M | 0M |
| Q2 2024 | 27 | 2M | 18.2% | 7 / 6 | 4 / 2 | 1M | 0M |
| Q1 2024 | 22 | 2M | 13.3% | 6 / 6 | 3 / 3 | 1M | 0M |
| Q4 2023 | 19 | 1M | 7.5% | 1 / 6 | 3 / 2 | 0M | 0M |
| Q3 2023 | 20 | 1M | 7.0% | 4 / 2 | 6 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of APRE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 80,925 | 0.64% | $72.23K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 19,622 | 0.16% | $15.74K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 7,197 | 0.06% | $6.42K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 5,851 | 0.05% | $5.22K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,100 | 0.02% | $1.87K | 0.00% | May 31, 2026 |
| Diversified Equity Alpha Master Portfolio | 289 | 0.00% | $232 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Oren Gilad | President/CEO, Director | 395,695 | 3.14% | Mar 16, 2026 |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | 43,528 | 0.35% | Apr 1, 2026 |
| Jean-Pierre Bizzari | Director | 4,180 | 0.03% | Jun 17, 2026 |
| Bernd R. Seizinger | Director | 48,910 | 0.39% | Jun 17, 2026 |
| Richard Peters | Director | 6,254 | 0.05% | Jun 17, 2026 |
| Gabriela Gruia | Director | 4,180 | 0.03% | Jun 17, 2026 |
| Rifat Pamukcu | Director | 22,689 | 0.18% | Jun 17, 2026 |
| Michael Grissinger | Director | 6,024 | 0.05% | Jun 17, 2026 |
| Marc Duey | Director | 259,892 | 2.06% | Jun 17, 2026 |
| John B. Henneman Iii | Director | 13,364 | 0.11% | Jun 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Grissinger Director | Jun 16, 2026 | Award | +3,135 | – | – | 6,024 |
| Marc Duey Director | Jun 16, 2026 | Award | +3,135 | – | – | 259,290 |
| Richard Peters Director | Jun 16, 2026 | Award | +3,135 | – | – | 6,254 |
| Rifat Pamukcu Director | Jun 16, 2026 | Award | +3,135 | – | – | 8,581 |
| John B. Henneman Iii Director | Jun 16, 2026 | Award | +3,135 | – | – | 13,364 |
| Jean-Pierre Bizzari Director | Jun 16, 2026 | Award | +3,135 | – | – | 4,180 |
| Bernd R. Seizinger Director | Jun 16, 2026 | Award | +3,135 | – | – | 48,910 |
| Gabriela Gruia Director | Jun 16, 2026 | Award | +3,135 | – | – | 4,180 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Mar 12, 2026 | Award | +10,095 | – | – | 43,528 |
| Oren Gilad President/CEO, Director | Mar 12, 2026 | Award | +20,175 | – | – | 393,895 |
| Oren Gilad President/CEO, Director | Jan 30, 2026 | Buy | +28,100 | $0.89 | $25.01K | 373,720 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Jan 30, 2026 | Buy | +5,700 | $0.89 | $5.07K | 33,433 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Dec 10, 2025 | Buy | +5,000 | $1.17 | $5.85K | 27,733 |
| Marc Duey Director | Dec 10, 2025 | Buy | +21,459 | $1.17 | $25.11K | 256,155 |
| Marc Duey Director | Jun 5, 2025 | Award | +1,045 | – | – | 234,696 |
| John B. Henneman Iii Director | Jun 5, 2025 | Award | +1,045 | – | – | 10,229 |
| Michael Grissinger Director | Jun 5, 2025 | Award | +1,045 | – | – | 2,889 |
| Rifat Pamukcu Director | Jun 5, 2025 | Award | +1,045 | – | – | 5,446 |
| Bernd R. Seizinger Director | Jun 5, 2025 | Award | +1,045 | – | – | 45,775 |
| Gabriela Gruia Director | Jun 5, 2025 | Award | +1,045 | – | – | 1,045 |
| Jean-Pierre Bizzari Director | Jun 5, 2025 | Award | +1,045 | – | – | 1,045 |
| Richard Peters Director | Jun 5, 2025 | Award | +1,045 | – | – | 3,119 |
| Oren Gilad President/CEO, Director | Apr 3, 2025 | Buy | +3,003 | $1.87 | $5.62K | 343,123 |
| Oren Gilad President/CEO, Director | Apr 3, 2025 | Buy | +2,497 | $1.80 | $4.49K | 345,620 |
| Oren Gilad President/CEO, Director | Mar 27, 2025 | Award | +6,725 | – | – | 340,120 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Mar 27, 2025 | Award | +3,365 | – | – | 22,733 |
| Oren Gilad President/CEO, Director | Oct 23, 2024 | Buy | +500 | $3.92 | $1.96K | 333,395 |
| Marc Duey Director | Oct 18, 2024 | Sale | −6,462 | $4.58 | $29.60K | 233,651 |
| Marc Duey Director | Oct 16, 2024 | Buy | +30,000 | $4.39 | $131.70K | 240,113 |
| Oren Gilad President/CEO, Director | Oct 15, 2024 | Buy | +250 | $2.90 | $725 | 332,895 |
| Marc Duey Director | Oct 14, 2024 | Buy | +190 | $2.58 | $490 | 210,113 |
| Oren Gilad President/CEO, Director | Oct 14, 2024 | Buy | +1,000 | $2.59 | $2.59K | 332,645 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Oct 11, 2024 | Buy | +50 | $2.46 | $123 | 19,368 |
| Bernd R. Seizinger Director | Oct 11, 2024 | Buy | +10,000 | $2.68 | $26.80K | 44,730 |
| Oren Gilad President/CEO, Director | Oct 10, 2024 | Buy | +150 | $2.54 | $381 | 331,645 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Oct 10, 2024 | Buy | +450 | $2.61 | $1.17K | 19,318 |
| Rifat Pamukcu Director | Jun 20, 2024 | Award | +1,045 | – | – | 4,401 |
| Bernd R. Seizinger Director | Jun 20, 2024 | Award | +1,045 | – | – | 34,730 |
| Marc Duey Director | Jun 20, 2024 | Award | +1,045 | – | – | 209,923 |
| John B. Henneman Iii Director | Jun 20, 2024 | Award | +1,045 | – | – | 9,184 |
| Richard Peters Director | Jun 20, 2024 | Award | +1,045 | – | – | 2,074 |
| Michael Grissinger Director | Jun 20, 2024 | Award | +1,045 | – | – | 1,844 |
| Nadeem Q. Mirza Chief Medical Officer | May 1, 2024 | Award | +6,730 | – | – | 6,730 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Mar 28, 2024 | Award | +3,365 | – | – | 18,868 |
| Oren Gilad President, CEO, Director | Mar 28, 2024 | Award | +6,725 | – | – | 331,495 |
| John B. Henneman Iii Director | Mar 13, 2024 | Buy | +6,860 | $7.29 | $50.01K | 8,139 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Mar 13, 2024 | Buy | +1,010 | $7.29 | $7.36K | 15,503 |
| Oren Gilad President, CEO, Director | Mar 13, 2024 | Buy | +2,000 | $7.29 | $14.58K | 324,770 |
| Bernd R. Seizinger Director | Mar 13, 2024 | Buy | +6,860 | $7.29 | $50.01K | 33,685 |
| Bernd R. Seizinger Director | Aug 23, 2023 | Award | +500 | – | – | 26,825 |
| Richard Peters Director | Aug 23, 2023 | Award | +500 | – | – | 1,029 |
| Rifat Pamukcu Director | Aug 23, 2023 | Award | +500 | – | – | 3,356 |
| John B. Henneman Iii Director | Aug 23, 2023 | Award | +500 | – | – | 1,279 |
| Michael Grissinger Director | Aug 23, 2023 | Award | +500 | – | – | 799 |
| Marc Duey Director | Aug 23, 2023 | Award | +500 | – | – | 208,878 |
| Bernd R. Seizinger Director | Jun 7, 2023 | Buy | +6,029 | $3.68 | $22.19K | 26,325 |
| Bernd R. Seizinger Director | Jun 6, 2023 | Buy | +4,068 | $3.63 | $14.77K | 20,296 |
| Oren Gilad President, CEO, Director | Mar 9, 2023 | Award | +4,000 | – | – | 322,770 |
| John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | Feb 27, 2023 | Award | +1,000 | $5.25 | $5.25K | 14,493 |
| John P. Hamill SrVP/CFO/Prin. Fin&Acctg. Off | Jan 30, 2023 | Award | +269,879 | – | – | 269,879 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.